Evaluation of Prevention and Treatment Effects of Fibroblast Growth Factor-21 in BLM-induced Pulmonary Fibrosis

Xiangxiang Wang,Shuang Li,Jinmiao Liu,Wenying Sun,Han Zhao,Qing Han,Yijia Liu,Xiaolin Cao,Qianhui Li,Yuhan Jin,Xiaochen Guo,Guiping Ren
DOI: https://doi.org/10.1007/s00210-023-02540-3
2023-01-01
Naunyn-Schmiedeberg s Archives of Pharmacology
Abstract:Pulmonary fibrosis is a progressive and fatal fibrotic lung disease and associated with a high mortality rate. In the study, the prevention and treatment effects of fibroblast growth factor-21 (FGF-21) in bleomycin (BLM)-induced pulmonary fibrosis were investigated in vivo and vitro. In the prevention of pulmonary fibrosis studies, the results showed that interdict of FGF-21 could reduce the related gene and protein expression levels of pulmonary fibrosis. In addition, FGF-21 significantly reduced both the aggregation of inflammatory cells and deposition of collagen in the lung by histopathology. In therapy of pulmonary fibrosis studies, the results indicated that treatment with FGF-21 resulted in an amelioration of the pulmonary fibrosis in mice with reductions of the pathological score, collagen deposition and transforming growth factor (TGF)-β and α-smooth muscle actin (α-SMA) expressions in the lung tissues at fibrotic stage, and late administration was also able to reduce the degree of pulmonary fibrosis and even better than these in the prevention group. Furthermore, BLM-induced THP-1 macrophage model was verified using FGF-21; the result showed that FGF-21 decreased the related gene expression level of pulmonary fibrosis. FGF-21 may have preventive and therapeutic effects on BLM-induced pulmonary fibrosis via inhibiting myofibroblast differentiation and inflammatory. Thus, FGF-21 represents a potential drug for the prevention and treatment of pulmonary fibrosis.
What problem does this paper attempt to address?